Recurrent gastric cancer sustaining a partial response after the nivolumab discontinuation because of immune-related adverse events: a case report.

Takaaki ArigamiDaisuke MatsushitaKeishi OkuboTakako TanakaKen SasakiMasahiro NodaYoshiaki KitaShinichiro MoriYusuke TsurudaHiroshi KuraharaTakao Ohtsuka

Published in: Surgical case reports (2020)

Acute irAE during nivolumab chemotherapy could be one of the crucial clinical factors to predict tumor suppression in patients with advanced gastric cancer.

Keyphrases

liver failure
drug induced
respiratory failure
neoadjuvant chemotherapy
locally advanced
squamous cell carcinoma
intensive care unit
extracorporeal membrane oxygenation
mechanical ventilation